UY30617A1 - SUBSTITUTED CARBAMATE DERIVATIVES OF 1- (9 - {[(2R) -2- {4-HIDROXI-3 - [(METILSULFONIL) AMINO] FENIL} ETIL] AMINO} NONIL) PIPERIDIN-4-ILO, ITS SALTS AND SOLVATES PHARMACEUTICALLY ACCEPTABLE AND APPLICATIONS - Google Patents

SUBSTITUTED CARBAMATE DERIVATIVES OF 1- (9 - {[(2R) -2- {4-HIDROXI-3 - [(METILSULFONIL) AMINO] FENIL} ETIL] AMINO} NONIL) PIPERIDIN-4-ILO, ITS SALTS AND SOLVATES PHARMACEUTICALLY ACCEPTABLE AND APPLICATIONS

Info

Publication number
UY30617A1
UY30617A1 UY30617A UY30617A UY30617A1 UY 30617 A1 UY30617 A1 UY 30617A1 UY 30617 A UY30617 A UY 30617A UY 30617 A UY30617 A UY 30617A UY 30617 A1 UY30617 A1 UY 30617A1
Authority
UY
Uruguay
Prior art keywords
amino
metilsulfonil
nonil
hidroxi
fenil
Prior art date
Application number
UY30617A
Other languages
Spanish (es)
Inventor
Lyn Howard Jones
Graham Lunn
David Anthony Price
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of UY30617A1 publication Critical patent/UY30617A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invencion se refiere a compuestos de formula (1) y a procesos para la preparacion de, intermedios usados en la preparacion de, composiciones que contienen y usos de, tales derivados. Los compuestos de acuerdo con la presente invencion son utiles en diversas enfermedades, trastornos y cuadros, en particular, enfermedades, trastornos y cuadros inflamatorios, alérgicos y respiratorios.The invention relates to compounds of formula (1) and processes for the preparation of intermediates used in the preparation of compositions containing and uses of such derivatives. The compounds according to the present invention are useful in various diseases, disorders and conditions, in particular diseases, disorders and inflammatory, allergic and respiratory conditions.

UY30617A 2006-10-04 2007-10-02 SUBSTITUTED CARBAMATE DERIVATIVES OF 1- (9 - {[(2R) -2- {4-HIDROXI-3 - [(METILSULFONIL) AMINO] FENIL} ETIL] AMINO} NONIL) PIPERIDIN-4-ILO, ITS SALTS AND SOLVATES PHARMACEUTICALLY ACCEPTABLE AND APPLICATIONS UY30617A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82809906P 2006-10-04 2006-10-04

Publications (1)

Publication Number Publication Date
UY30617A1 true UY30617A1 (en) 2008-05-31

Family

ID=38947725

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30617A UY30617A1 (en) 2006-10-04 2007-10-02 SUBSTITUTED CARBAMATE DERIVATIVES OF 1- (9 - {[(2R) -2- {4-HIDROXI-3 - [(METILSULFONIL) AMINO] FENIL} ETIL] AMINO} NONIL) PIPERIDIN-4-ILO, ITS SALTS AND SOLVATES PHARMACEUTICALLY ACCEPTABLE AND APPLICATIONS

Country Status (25)

Country Link
US (1) US20080090873A1 (en)
EP (1) EP2074094A1 (en)
JP (1) JP2010505810A (en)
KR (1) KR20090050104A (en)
CN (1) CN101522622A (en)
AP (1) AP2009004791A0 (en)
AR (1) AR063118A1 (en)
AU (1) AU2007303909A1 (en)
BR (1) BRPI0719270A2 (en)
CA (1) CA2665385A1 (en)
CL (1) CL2007002791A1 (en)
CO (1) CO6180437A2 (en)
CR (1) CR10700A (en)
EA (1) EA200900337A1 (en)
IL (1) IL197244A0 (en)
MA (1) MA30778B1 (en)
MX (1) MX2009002209A (en)
NO (1) NO20090910L (en)
PE (1) PE20080831A1 (en)
RS (1) RS20090137A (en)
TN (1) TN2009000112A1 (en)
TW (1) TW200823185A (en)
UY (1) UY30617A1 (en)
WO (1) WO2008041095A1 (en)
ZA (1) ZA200901320B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
JP5801997B2 (en) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Dosing unit, dosing unit pack, and inhaler for inhaling a combination of drugs
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
ITRM20110083U1 (en) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire PLATE FOR THE CONSTRUCTION OF TRUCKS FOR AIRPLANES
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
BR112015013628A2 (en) 2012-12-18 2017-07-11 Almirall Sa cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
TWI643853B (en) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
TWI641373B (en) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES
TW201517906A (en) 2013-07-25 2015-05-16 Almirall Sa Combinations comprising MABA compounds and corticosteroids
TW201617343A (en) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities
CN106336406B (en) * 2015-07-10 2020-01-03 四川海思科制药有限公司 Having beta2Octahydropentalene derivatives with receptor agonistic and M receptor antagonistic activity and their medical use
CA3047023C (en) 2016-12-14 2022-05-31 Beijing Showby Pharmaceutical Co., Ltd. Class of bifunctional compounds with quaternary ammonium salt structure
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
ES2927715T3 (en) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc p38 kinase inhibitors reduce the expression of dux4 and the genes that follow it for the treatment of FSHD
WO2019110521A1 (en) * 2017-12-04 2019-06-13 Friedrich-Alexander-Universität Erlangen-Nürnberg Fluorophenyl substituted muscarinic receptor ligands with selectivity for m3 over m2
WO2021260441A1 (en) 2020-06-26 2021-12-30 Mylan Pharma Uk Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
PE20040950A1 (en) * 2003-02-14 2005-01-01 Theravance Inc BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
WO2004089892A2 (en) * 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
JP4616264B2 (en) * 2003-05-28 2011-01-19 セラヴァンス， インコーポレーテッド Azabicycloalkane compounds as muscarinic receptor antagonists
CA2553293C (en) * 2004-01-22 2010-12-14 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
US7320990B2 (en) * 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound

Also Published As

Publication number Publication date
CR10700A (en) 2009-04-24
TN2009000112A1 (en) 2010-08-19
KR20090050104A (en) 2009-05-19
EA200900337A1 (en) 2009-10-30
PE20080831A1 (en) 2008-06-20
MX2009002209A (en) 2009-03-16
BRPI0719270A2 (en) 2014-03-11
TW200823185A (en) 2008-06-01
AP2009004791A0 (en) 2009-04-30
EP2074094A1 (en) 2009-07-01
CO6180437A2 (en) 2010-07-19
RS20090137A (en) 2010-06-30
IL197244A0 (en) 2009-12-24
US20080090873A1 (en) 2008-04-17
AR063118A1 (en) 2008-12-30
NO20090910L (en) 2009-03-24
CN101522622A (en) 2009-09-02
ZA200901320B (en) 2010-04-28
CA2665385A1 (en) 2008-04-10
CL2007002791A1 (en) 2008-04-11
AU2007303909A1 (en) 2008-04-10
WO2008041095A1 (en) 2008-04-10
JP2010505810A (en) 2010-02-25
MA30778B1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
UY30617A1 (en) SUBSTITUTED CARBAMATE DERIVATIVES OF 1- (9 - {[(2R) -2- {4-HIDROXI-3 - [(METILSULFONIL) AMINO] FENIL} ETIL] AMINO} NONIL) PIPERIDIN-4-ILO, ITS SALTS AND SOLVATES PHARMACEUTICALLY ACCEPTABLE AND APPLICATIONS
PA8622001A1 (en) SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES
ECSP066701A (en) SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES
ECSP088717A (en) AMINA DERIVATIVES
NI201000085A (en) DERIVATIVES BIS - (SULFONYLAMINE) IN THERAPY 066.
CR8649A (en) FORMAMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES
ECSP11010754A (en) USEFUL TRIAZOL DERIVATIVES FOR THE TREATMENT OF DISEASES
GT200400116A (en) USED 2-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES.
PA8627001A1 (en) COMPOUNDS FOR THE TREATMENT OF DISEASES
UY29394A1 (en) SUBSTITUTED DERIVATIVES OF N- (5- (2-PROPILAMINE.1.HYDROXYETHYL) -2-HDROXIFENIL) METHANE SULFONAMIDE, PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND APPLICATIONS.
CU23801B7 (en) PIRAZOL ANALOGS
UY28819A1 (en) FORMAMIDA DERIVATIVES FOR THE TREATMENT OF DISEASES
ECSP066700A (en) SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES
CU23532B7 (en) SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES
CU23537B7 (en) SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES
DOP2007000054A (en) AMINA DERIVATIVES
DOP2005000037A (en) USEFUL COMPOUNDS FOR THE TREATMENT OF DISEASES
CR8513A (en) SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES
ECSP066854A (en) USEFUL COMPOUNDS FOR THE TREATMENT OF DISEASES
DOP2005000043A (en) COMPOUNDS FOR THE TREATMENT OF DISEASES
DOP2004000902A (en) USEFUL COMPOUNDS FOR THE TREATMENT OF DISEASES
UY28816A1 (en) COMPOUNDS FOR THE TREATMENT OF DISEASES
DOP2007000062A (en) ANTIFUNGAL AGENTS

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170725